Go Pro
→ Should You Convert a Traditional IRA to a Roth After 60? (From SmartAsset) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
$0.50
+0.1%		$0.71
$0.43
▼
$2.89
$1.37M0.89157,485 shs33,409 shs
Biotricity, Inc. stock logo
BTCY
Biotricity
$0.07
+6.9%		$0.10
$0.06
▼
$0.75
$1.50M1.1651,529 shs242,288 shs
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
$1.80
-1.1%		$4.54
$1.77
▼
$136.29
$1.28M0.62822,520 shs481,175 shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.31
$0.31
$0.25
▼
$12.93
$442K-0.062.28 million shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
0.00%-3.88%-19.35%-64.06%-79.33%
Biotricity, Inc. stock logo
BTCY
Biotricity
0.00%-17.26%-43.64%-47.76%-88.14%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
0.00%-26.32%-56.97%-61.11%-98.19%
Venus Concept Inc. stock logo
VERO
Venus Concept
0.00%0.00%0.00%0.00%-86.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
$0.50
+0.1%		$0.71
$0.43
▼
$2.89
$1.37M0.89157,485 shs33,409 shs
Biotricity, Inc. stock logo
BTCY
Biotricity
$0.07
+6.9%		$0.10
$0.06
▼
$0.75
$1.50M1.1651,529 shs242,288 shs
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
$1.80
-1.1%		$4.54
$1.77
▼
$136.29
$1.28M0.62822,520 shs481,175 shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.31
$0.31
$0.25
▼
$12.93
$442K-0.062.28 million shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
0.00%-3.88%-19.35%-64.06%-79.33%
Biotricity, Inc. stock logo
BTCY
Biotricity
0.00%-17.26%-43.64%-47.76%-88.14%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
0.00%-26.32%-56.97%-61.11%-98.19%
Venus Concept Inc. stock logo
VERO
Venus Concept
0.00%0.00%0.00%0.00%-86.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
1.00
SellN/AN/A
Biotricity, Inc. stock logo
BTCY
Biotricity
0.00
N/AN/AN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
1.00
SellN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest VERO, GCTK, BTCY, and BBLG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
N/AN/AN/AN/A$3.00 per shareN/A
Biotricity, Inc. stock logo
BTCY
Biotricity
$12.06M0.12N/AN/A($1.30) per share-0.06
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/A$41.93 per shareN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
$58.88M0.01N/AN/A$4.30 per share0.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-$3.11M-$1.37N/AN/AN/AN/A-57.87%-53.65%11/13/2026 (Estimated)
Biotricity, Inc. stock logo
BTCY
Biotricity
-$14.09M-$0.14N/AN/AN/A-80.42%N/A-188.47%11/12/2026 (Estimated)
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
-$19.39M-$137.63N/AN/AN/AN/A-2,135.52%-290.22%N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
-$47M-$48.84N/AN/AN/A-92.76%-1,904.25%-85.22%N/A

Latest VERO, GCTK, BTCY, and BBLG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-$0.39-$0.43-$0.04-$0.43N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
N/AN/AN/AN/AN/A
Biotricity, Inc. stock logo
BTCY
Biotricity
N/AN/AN/AN/AN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
N/A
8.67
8.67
Biotricity, Inc. stock logo
BTCY
Biotricity
N/A
0.23
0.10
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
0.08
0.46
0.46
Venus Concept Inc. stock logo
VERO
Venus Concept
1.59
0.90
0.59

Institutional Ownership

CompanyInstitutional Ownership
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
34.30%
Biotricity, Inc. stock logo
BTCY
Biotricity
3.89%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
10.92%
Venus Concept Inc. stock logo
VERO
Venus Concept
87.41%

Insider Ownership

CompanyInsider Ownership
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
5.00%
Biotricity, Inc. stock logo
BTCY
Biotricity
1.60%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
5.90%
Venus Concept Inc. stock logo
VERO
Venus Concept
28.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
22.76 million2.62 millionNot Optionable
Biotricity, Inc. stock logo
BTCY
Biotricity
4620.08 million22.08 millionNo Data
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
15710,000664,000Not Optionable
Venus Concept Inc. stock logo
VERO
Venus Concept
4101.42 million1.03 millionNot Optionable

Recent News About These Companies

Venus Concept stock reports CEO change effective September 7
September 25 at 2:48 PM  |  ad-hoc-news.deA
Venus Concept Obtains Exclusive Distribution Rights for the HIRONIC Doublo 2.0 Device in US and Canada
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334139/0/en/venus-concept-obtains-exclusive-distribution-rights-for-the-hironic-doublo-2-0-device-in-us-and-canada.html
Venus Concept Announces Senior Management Changes
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294518/0/en/venus-concept-announces-senior-management-changes.html
Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger
April 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/01/3266701/0/en/venus-concept-announces-completion-of-common-stock-sale-and-short-form-merger.html
Venus Concept extends bridge financing and eases covenants
February 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/venus-concept-extends-bridge-financing-and-eases-covenants?utm_source=marketbeat.com&utm_medium=referral
Venus Concept stock plummets after announcing Nasdaq delisting plans
January 21, 2026  |  uk.investing.comhttps://uk.investing.com/news/stock-market-news/venus-concept-stock-plummets-after-announcing-nasdaq-delisting-plans-93CH-4463879
Venus Concept to exit NASDAQ and end SEC reporting obligations
January 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/venus-concept-to-exit-nasdaq-and-end-sec-reporting-obligations/ar-AA1UEWcO
Venus Concept to Voluntarily Delist and Deregister Shares
January 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/venus-concept-to-voluntarily-delist-and-deregister-shares?utm_source=marketbeat.com&utm_medium=referral
Venus Concept Inc. Announces Voluntary Delisting from NASDAQ and Deregistration with SEC
January 21, 2026  |  quiverquant.comQ
Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC
January 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/21/3222676/0/en/venus-concept-announces-intention-to-voluntary-delist-from-nasdaq-and-deregister-with-sec.html
Top 3 Health Care Stocks You May Want To Dump In January
January 20, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/short-ideas/26/01/50002177/top-3-health-care-stocks-you-may-want-to-dump-in-january?utm_source=snapi
Venus Concept Surges 405% as Madryn Asset Management Secures 91% Stake
January 16, 2026  |  sohu.comS
Why is VERO stock up 300% today?
January 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/markets/why-is-vero-stock-up-300-today/ar-AA1UmaR5
Venus Concept (VERO) Stock Explodes Over 300% As Majority Owner Takes Control
January 16, 2026  |  blockonomi.comhttps://blockonomi.com/venus-concept-vero-stock-explodes-over-300-as-majority-owner-takes-control/
Dr. Koray Erdoğan’s U.S.-Patented KE-Bot Sets a New Benchmark in Hair Transplantation
January 16, 2026  |  independent.co.ukI
Venus Concept Secures Short-Term Debt Relief Extension
January 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VERO/pressreleases/36957839/venus-concept-secures-short-term-debt-relief-extension/
Hair Restoration Market 2025 Industry Growth Statistics, Revenue Projections, Future Trends, and Forecast to 2033
January 8, 2026  |  taiwannews.com.twT
Fans swear these at-home gadgets can make your hair grow — but do they really work?
December 4, 2025  |  msn.comhttps://www.msn.com/en-us/health/medical/fans-swear-these-at-home-gadgets-can-make-your-hair-grow-but-do-they-really-work/ar-AA1REVow
Venus Concept Amends Loan Agreement with Madryn Health
December 2, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/venus-concept-amends-loan-agreement-with-madryn-health/ar-AA1RAJFA
Venus Concept Faces Mixed Fortunes in Earnings Call
November 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/venus-concept-faces-mixed-fortunes-in-earnings-call/ar-AA1Qpp0W

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bone Biologics stock logo

Bone Biologics NASDAQ:BBLG

$0.50 +0.00 (+0.06%)
Closing price 04:00 PM Eastern
Extended Trading
$0.49 -0.01 (-1.07%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Biotricity stock logo

Biotricity NASDAQ:BTCY

$0.07 +0.00 (+6.86%)
As of 03:20 PM Eastern

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

GlucoTrack stock logo

GlucoTrack NASDAQ:GCTK

$1.80 -0.02 (-1.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.78 -0.03 (-1.39%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

Venus Concept stock logo

Venus Concept NASDAQ:VERO

$0.31 0.00 (0.00%)
As of 09/25/2026

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas